This phase IV trial tests whether acetylcysteine (N-acetylcysteine [NAC]) works for smoking cessation in cigarette-cannabis co-users. NAC has been shown to improve cognition and impulsivity, which in turn may improve control in behavior. NAC may improve quite rates of cigarettes in people who use both cigarettes and cannabis.
Additional locations may be listed on ClinicalTrials.gov for NCT04627922.
Locations matching your search criteria
United States
California
San Francisco
Veterans Affairs Medical Center - San FranciscoStatus: Active
Contact: Ellen Herbst
Phone: 415-221-4810
PRIMARY OBJECTIVE:
I. To determine NAC's efficacy in decreasing cigarette use, nicotine dependence levels, and craving; and cannabis use, cannabis use severity levels, and craving.
EXPLORATORY OBJECTIVE:
I. Examination of changes in neurocognition with NAC and their potential mediational effects on cigarette and cannabis use outcomes.
OUTLINE: Participants are randomized to 1 of 2 groups.
GROUP I: Participants receive acetylcysteine orally (PO) twice daily (BID) for 8 weeks. Participants also participate in 30-minute cognitive behavioral therapy (CBT) sessions addressing both tobacco and cannabis use weekly over 8 weeks.
GROUP II: Participants receive placebo PO BID for 8 weeks. Participants also participate in 30-minute CBT sessions addressing both tobacco and cannabis use weekly over 8 weeks.
After completion of study treatment, participants are followed up at 12 weeks.
Lead OrganizationUniversity of California San Francisco
Principal InvestigatorEllen Herbst